![](https://netrf.org/wp-content/uploads/2018/03/Ronny-Allan-ENETs-300x228.jpg)
Research Today is the Treatment of Tomorrow
by Ronny Allan, NET Patient Activist Doctors and scientists are always looking for better ways to care for patients with cancer; they are looking for
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
by Ronny Allan, NET Patient Activist Doctors and scientists are always looking for better ways to care for patients with cancer; they are looking for
New treatment for GI and pancreatic NETs The U.S. Food and Drug Administration (FDA) has approved Peptide Receptor Radionuclide Therapy (PRRT) with a new radiopharmaceutical for
World renown laboratory in the Netherlands to grown min-organs in Petri dishes to speed up NET drug testing.
Even those who did not know her were inspired by the stories of Meg’s positive, generous spirit, her sense of humor, and ability to squeeze so much life into her 31+years. Nurse Meg took care of us all and is forever in our hearts—forever running alongside encouraging us to dream bigger and live stronger—and find and inspire laughter and joy each day.
There is a critical need to develop improved diagnostic tools for non-invasive, early detection of NETs in a broader range of patients. New grant-funded research will work towards this goal.
He is a pioneer whose work has helped extend the horizon of cancer care, creating a new category of individualized immunotherapy. Carl June, MD, has conducted 25 years of scientific research to advance CAR T-cell therapy. And all that knowledge is now helping to tackle NETs.
Imagine being able to program your immune system to launch one million minuscule heat-seeking missiles, whose sole purpose is to find and kill cancer cells. This is the basic premise behind an emerging form of immunotherapy, called CAR T-cell therapy, which genetically modifies an individual’s immune system to find, bind to, and kill cancer cells.
It can be difficult to biopsy tissue from pancreatic neuroendocrine tumors (PNETs) for genomic profiling. To help create safe and non-invasive tests for genomic mutations before, during, and after treatment in PNET patients, NETRF is funding researchers that are testing a novel alternative known as a “liquid biopsy.”
The 7th annual memorial golf tournament on behalf of Jacob Carwile took place on a hot July day at the Hidden Valley Golf & Country Club, Livingston, Tennessee. Like every year, Earl Carwile set out early to place sponsorship signs at every tee before the first round of golfers headed out onto the nine-hole course for the first of two tee times.
Study shows rising incidence and prevalence of NETs. Plus people living longer with neuroendocrine cancer. This means more people living with NETs.